Back
30 July 2025
As reported by the ITA previously, a sample collected during a targeted out-of-competition test on 17 February 2024 from Tuğrulhan Erdemir had returned an Atypical Finding (ATF)¹ for the prohibited substance “hydrochlorothiazide”.
Hydrochlorothiazide is prohibited under the WADA Prohibited list as a diuretic and masking agent (S.5). It is prohibited at all times (in-competition and out-of-competition) and can be used by athletes to excrete water for rapid weight loss.
On 24 July 2024, the CAS ADD issued an order confirming the provisional suspension imposed on Tuğrulhan Erdemir which also extended to the Olympic Games Paris 2024.
On 18 November 2024, and as reported by the ITA, CAS ADD sanctioned Tuğrulhan Erdemir with 2 years of ineligibility.
On 24 July 2025, further to an appeal filed by the athlete against the CAS ADD decision and fully-fledged written and oral proceedings pertaining to the merits of the case, the CAS dismissed the athlete’s appeal thus confirming that the athlete committed an anti-doping rule violation (ADRV) for the presence of a prohibited substance and the sanction of 2 years of ineligibility to be served until 9 July 2026. Moreover, all results obtained by the athlete from 17 February 2024 (date of the ADRV) until 10 July 2024 (date of the provisional suspension) are disqualified.
The ITA will not comment further on the matter.
¹ A report from a WADA-accredited laboratory or other WADA-approved laboratory which requires further investigation as provided by the International Standard for Laboratories or related Technical Documents prior to the determination of an Adverse Analytical Finding.
